Dr. Carles Galdeano recently participated in the Discovery On Target 2025 international conference held in Boston (USA), where he presented his work titled “A First-in-Class TET2 Activator as a New Therapeutic Strategy Against Cancer.” During his talk, he introduced the development of a pioneering TET2 activator as a novel therapeutic approach against cancer, showing promising results that highlight its potential to restore altered epigenetic functions in tumor cells. His presentation generated great interest among the scientific community and reinforces his group’s leadership in the discovery of innovative drugs with clinical impact.